Current clinical trials

Current clinical trials

Bladder cancer

  • THOR-2 (42756493BLC2001)
    A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions: https://clinicaltrials.gov/ct2/show/NCT04172675
  • SUNRise-1 TAR-200 (17000139BLC2001)
    Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy: https://clinicaltrials.gov/ct2/show/NCT04640623

Adjuvant / Neoadjuvant:

  • CA017-078
    A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer: https://clinicaltrials.gov/ct2/show/NCT03661320

Metastatic:

  • EV302 (SGN22E-003)
    An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: https://clinicaltrials.gov/ct2/show/NCT04223856

Breast cancer

  • D9673R00005
    A Multicountry, Multicentre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer: https://www.clinicaltrials.gov/ct2/show/NCT04857619 
  • FINER (MA40 / BCT2101)
    A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor: https://www.clinicaltrials.gov/ct2/show/NCT04650581
  • ZEST (213831)
    A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy: https://www.clinicaltrials.gov/ct2/show/NCT04915755
  • IMpassion030
    A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer: https://clinicaltrials.gov/ct2/show/NCT03498716
  • INAVO120 (WO41554)
    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer: https://clinicaltrials.gov/ct2/show/NCT04191499
  • KEYNOTE-B49 (MK-3475-B49)
    A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49): https://clinicaltrials.gov/ct2/show/NCT04895358
  • OP-1250-001
    A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer: https://clinicaltrials.gov/ct2/show/NCT04505826

Cardiovascular

  • ADVANCE Outcomes (ROR-PH-301)
    A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 Pulmonary Arterial Hypertension https://clinicaltrials.gov/ct2/show/NCT03626688
  • ADVANCE Capacity  (ROR-PH-302)
    A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy: https://clinicaltrials.gov/ct2/show/NCT04084678
  • MK-5475-007
    A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension: https://clinicaltrials.gov/ct2/show/NCT04732221

Depression

Macquarie University is seeking participants in the Sydney area for a clinical trial investigating low doses of psilocybin ‘microdosing’ for the treatment of moderate depression.

Participants will undergo comprehensive psychiatric screening, and if eligible, will take part in a 10-week intervention with six weeks of drug treatment (two microdoses each week). All sessions take place at Macquarie University, with transport provided.

Learn more about what's involved and how to participate in the MicroDep trial.

Endocrinology

  • 1366-002
    Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease: https://clinicaltrials.gov/ct2/show/NCT04736628
  • 1366-0005
    Randomised, Double-blind (Within Dose Groups), Placebo-controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Diabetic Kidney Disease: https://clinicaltrials.gov/ct2/show/NCT04750577
  • TCH-306  (FORESIGHT)
    A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt): https://clinicaltrials.gov/ct2/show/NCT04615273

Gastrointestinal cancer

Gastroenterology

  • APD334-202 (CULTIVATE)
    A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease (CULTIVATE): https://clinicaltrials.gov/ct2/show/NCT04173273
  • ARTEMIS-UC (PR200-102)
    A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis: https://www.clinicaltrials.gov/ct2/show/NCT04996797 
  • GALAXI
    A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease: https://clinicaltrials.gov/ct2/show/NCT0346641
  • PRELUDE (PR100-105)
    A Study to Assess the Genotype of Subjects with Diagnosis of Ulcerative Colitis or Crohn’s Disease
  • STOPit
    Study of Tofacitinib for the treatment of chronic Pouchitis

Head & Neck Cancer

  • TACTI-003
    TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC): https://clinicaltrials.gov/ct2/show/NCT04811027

Kidney cancer

  • D5086C00001 (SAMETA)
    A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA): https://clinicaltrials.gov/ct2/show/NCT05043090
  • iPREDICT (IAB-CD8-203)
    A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy: https://www.clinicaltrials.gov/ct2/show/NCT05013099 
  • LiteSpark (MK-6482-022)
    A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022): https://www.clinicaltrials.gov/ct2/show/NCT05239728 
  • MK-6482-012
    An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC): https://clinicaltrials.gov/ct2/show/NCT04736706
  • UNICAB
    A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-
    Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy (ANZUP 1802): https://clinicaltrials.gov/ct2/show/NCT03685448
  • ZIRCON
    A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses: https://clinicaltrials.gov/ct2/show/NCT03849118

Lung Cancer

  • ACT16849
    A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma: https://clinicaltrials.gov/ct2/show/NCT04914897

Lymphoedema

  • LYT-100-2020-01
    A Phase 1 Multiple Ascending Dose and Food Effect Study in Healthy Volunteers to Determine the Pharmacokinetics and Maximally Tolerated Dose of Deupirfenidone (LYT-100) Followed by a Randomized Double-Blind Placebo-Controlled Phase 2a in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema: https://clinicaltrials.gov/ct2/show/NCT04243837

Mental Health

  • MicroDep-01
    A Double-Blind Randomised Controlled Trial of Microdosing with Psilocybin to treat Moderate Depression:
    More Information

Multi-tumour trials

  • ADG116-1003
    A Phase 1b, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors: https://clinicaltrials.gov/ct2/show/NCT04501276
  • BAT-6021-002-CR
    A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors: https://clinicaltrials.gov/ct2/show/NCT05073484
  • DB-1303-O-1001
    A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors: https://www.clinicaltrials.gov/ct2/show/NCT05150691 
  • ICP-CL-00303
    A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations: https://clinicaltrials.gov/ct2/show/NCT04565275
  • MK-0482-001
    A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors: https://clinicaltrials.gov/ct2/show/NCT03918278
  • SHR-A1811-I-101
    A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects: https://clinicaltrials.gov/ct2/show/NCT04446260
  • YH002004
    A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors: https://www.clinicaltrials.gov/ct2/show/NCT05169697

Neurology

Ophthalmology

  • CDDO001F12201 (FUSION)
    A 52 Week Randomized, Single-masked, Multicenter Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia in Children 4-7 Years of Age With an Open-label Substudy of Binocular Videogames in Children 8-12 Years of Age: https://clinicaltrials.gov/ct2/show/NCT04784390
  • PQ-110-001
    A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus: https://clinicaltrials.gov/ct2/show/NCT04565756

Prostate cancer

Metastatic:

  • 20510 (RADIANT)
    A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH: https://clinicaltrials.gov/ct2/show/NCT04597125
  • AMPLITUDE (67652000PCR3002)
    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC):
    https://clinicaltrials.gov/ct2/show/NCT04497844
  • ARANOTE (21140)
    A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC): https://clinicaltrials.gov/ct2/show/NCT04736199
  • ANZUP 1901 (ENZA-p)
    ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901): https://clinicaltrials.gov/ct2/show/NCT04419402
  • CONTACT-02 (XL184-315)
    A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer: https://clinicaltrials.gov/ct2/show/NCT04446117
  • IMP4297-202
    A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment: https://clinicaltrials.gov/ct2/show/NCT04822961
  • JPCM
    Phase 2, randomized, double-blind, placebo-controlled study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in patients with metastatic castration-resistant prostate cancer: https://clinicaltrials.gov/ct2/show/NCT03706365
  • KEYNOTE-641
    A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC): https://clinicaltrials.gov/ct2/show/NCT03834493
  • PRIMORDIUM (56021927PCR3015)
    A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Follow-up of PSMA-PET-Negative Patients: https://clinicaltrials.gov/ct2/show/NCT04557059
  • SHR3162-III-305
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: https://clinicaltrials.gov/ct2/show/NCT04691804

Respiratory

  • BTVA Registry
    Australian Registry of Bronchoscopic Thermal Vapour Ablation (BTVA) for Lung Volume Reduction in the treatment of patients with severe COPD:
  • Titania (D9180C00004)
    A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations: https://www.clinicaltrials.gov/ct2/show/NCT05158387

Skin Cancer

  • ACT16845
    A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers: https://clinicaltrials.gov/ct2/show/NCT04913220

Surgery

  • REGENETEN.2020.01
    A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of ARCR Augmented With REGENETEN™ Bioinductive Implant System in Full-thickness Tears (Large or Massive) Repair Versus ARCR Alone: https://clinicaltrials.gov/ct2/show/NCT04450342

Content owner: Faculty of Medicine, Health and Human Sciences Last updated: 04 Oct 2024 12:16pm

Back to the top of this page